SEC Form 4 · accession 0001104659-18-006855
Mersana Therapeutics, Inc. · MRSN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Donald A Bergstrom
Officer — Chief Medical Officer
Period of report
Feb 2, 2018
Accepted (ET)
Feb 6, 2018 · 4:24 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001442836
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F1 | $14.23 | Feb 2, 2018 | A | 56,884 | A | — | Feb 1, 2028 | Common Stock | 56,884 | 56,884 | D |
Explanation of responses
- F1The options vest in equal quarterly installments over the first four years after the vesting commencement date, February 2, 2018.